Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor
prognosis and for decades no approved drug has been available to treat this serious …

Background: Myeloid-derived suppressor cells (MDSCs) are implicated in the complex
interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease …

Background For patients with steroid-refractory acute graft-versus-host disease (SR-
aGVHD), effective second-line regimens are urgently needed. Mesenchymal stromal cells …

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor
cells into patients with hematologic disorders with the goal of re-establishing normal …

Steroids remain the initial therapy for acute graft-vs.-host disease (AGVHD). Strategies to
improve response and minimize steroid exposure are needed. We report results of a …

Immunotherapy with chimeric antigen receptor T (CAR-T cells) has been recently approved
for patients with relapsed/refractory B-lymphoproliferative neoplasms. Along with great …

The skin is the outermost mechanical barrier where dynamic immune reactions take place
and is the most commonly affected site in both acute and chronic graft-versus-host disease …

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) detected in the liver
has been considered a severe complication of hematopoietic stem cell transplantation …

Acute graft-versus-host disease (aGVHD) is a serious complication after stem cell
transplantation and is associated with high non-relapse mortality. If steroid treatment as first …

Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant
haematological diseases. Despite continuous improvements in pre-and post-transplantation …